SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

Shiba Inu is currently a focal point for community debate, as traders weigh the potential for a rebound against long-standing skepticism regarding its ecosystem development and burn mechanisms. While some participants are actively accumulating in hopes of a future rally, others express deep frustration, citing the lack of significant price appreciation and calling into question the project's long-term utility.

Anthropic

Anthropic is trending as it rapidly expands its computing infrastructure through major deals with SpaceX and AMD, while aggressively competing in the enterprise AI space with its latest Claude models. The community remains focused on the company's valuation trajectory, high infrastructure spending, and the intense race to maintain a competitive advantage against other frontier AI labs ahead of a potential IPO.

Select Sector SPDR Trust (The) - State Street Technology Select Sector SPDR ETF

Technology Select Sector SPDR Fund

Technology sector funds like XLK are facing heightened volatility as investors pivot from broad AI spending excitement to demanding concrete evidence of revenue and margin growth. The market is currently grappling with a rotation toward defensive sectors and financials, leaving tech at a pivotal technical test as traders weigh AI-driven cloud demand against concerns over elevated valuations and the impact of evolving U.S. trade policy.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending as the community remains deeply divided between long-term investors adding to their positions during market-wide dips and skeptics who frequently label the project a scam due to its stagnant performance and perceived lack of utility. Traders are currently focused on technical resistance levels and debating whether the recent launch of related ecosystem projects indicates abandonment of the main token or a broader strategic expansion.

OpenAI

OpenAI is trending as investors monitor its progress toward a highly anticipated IPO, while the company faces intensifying competition from rival labs and increased regulatory scrutiny regarding AI safety and infrastructure spending. Community discussions are heavily focused on the viability of its circular financing models, ongoing legal battles, and the strategic implications of its high-profile partnerships.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is currently facing intense selling pressure, leading to community-wide anxiety as the token trends toward multi-year lows despite its enterprise use cases. While some investors are aggressively accumulating to lower their cost basis, others are voicing deep frustration and skepticism regarding the project's long-term viability compared to other major crypto assets.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Community members are actively debating the long-term utility of this Bitcoin-native asset, with supporters touting its decentralized structure while skeptics caution against its volatile price action and distribution. The conversation remains heavily focused on its role as a potential store of value within the Bitcoin ecosystem and the strength of its dedicated following.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is trending as it faces a high-stakes legal challenge from 12 state attorneys general attempting to block its $110 billion merger with Warner Bros. Discovery despite prior federal approval. Community discussion is polarized, with many investors viewing the lawsuit as politically motivated theater while others express significant concern over the potential for costly ticking fees and further financial strain on the company.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is gaining momentum as investors weigh its shift toward a paid subscription model for data feeds against the broader potential of its oracle services in the RWA and AI sectors. The community is actively debating the project's long-term utility and competitive positioning against incumbents while closely monitoring institutional adoption developments.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Rigel Pharmaceuticals is currently trending as investors focus on recent in-licensing of VEPPANU, the first FDA-approved PROTAC therapy, which the community views as a potential blockbuster growth driver for the oncology franchise. While the stock has faced downward pressure, long-term investors are highlighting its status as a profitable commercial biotech with a low valuation, eagerly awaiting further pipeline data and the potential for a positive valuation shift.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HCA Q2 Earnings Beat on Strong Admissions, 2026 Outlook Revised

HCA tops Q2 EPS estimates on higher admissions and revenue per admission but trims parts of its 2026 guidance as higher expenses and weaker surgical volumes weigh on results.

What Makes Charles River Laboratories (CRL) a Strong Momentum Stock: Buy Now?

Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Abbott Q2 Earnings & Revenues Top Estimates, Stock Up in Pre-market

ABT tops Q2 earnings and revenue estimates and lifts 2026 EPS guidance, while Medical Devices and Cancer Diagnostics fuel growth despite Nutrition weakness.

Is Perspective Therapeutics, Inc. (CATX) Stock Outpacing Its Medical Peers This Year?

Here is how Perspective Therapeutics (CATX) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.

Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call

Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2026 financial results on Wednesday, August 5th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 5th, at 9:00 a.m. ET. Investors will have the...

Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?

Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches

Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps...

ICON Stock and the CRO Trends Shaping Its Next Growth Phase

ICLR is tapping CRO demand, AI workflows and wider trial access, but uneven revenue trends and margin resets keep its earnings recovery in focus.

Medpace Growth Trends Show How CRO Demand Is Shifting in 2026

MEDP's 2026 outlook highlights shifting CRO demand, longer award-to-revenue timing and steady margins, while AI investment delays near-term productivity gains.

Medpace Stock Outlook Turns on Backlog Quality and Cancellations

MEDP's outlook hinges on whether strong backlog quality and metabolic demand can offset rising cancellations and softer proposal activity.

Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The Research Models and Services segment includes its insourcing solutions business and Charles River accelerator and development lab footprint. The Discovery and Safety Assessment segment offers regulatory-required safety testing of potential new drugs, vaccines, industrial and agricultural chemicals, consumer products, veterinary medicines, and medical devices. The Manufacturing Solutions segment focuses on microbial solutions and biologics solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.

Charles River Laboratories International Inc.

Charles River Labs Stock Soars On Strategic Review Plan With Elliott: Retail Investors Optimistic

Equity

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards another losing week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$226.58
Prev Close	$229.29
Open	$230.23
Dividend Yield	0.00%
50-Day Moving Average	$196.69
Beta	1.43
Avg. Volume	848,761.35
PE Ratio	-60.26

52-Week High	$238.85
52-Week Low	$144.26
Market Capitalization	$10.91B
EPS (Annual)	-$2.91
Price to Book	3.71
Revenue Per Employee	$203,826.50

Feed

News

Sentiment

Earnings

Fundamentals

Info

CRLCharles River Laboratories International Inc.

Latest CRL News